Advertisement
Advertisement
TNGX
Tango Therapeutics, Inc.
24.95
USDSponsored
+1.45
+6.17%
May 13, 15:18 UTC -4
Open
TNGX Earnings Reports
Positive Surprise Ratio
TNGX beat 12 of 18 last estimates.
67%
Next Report
Today
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.31
Implied change from Q4 25 (Revenue/ EPS)
--
/+10.71%
Implied change from Q1 25 (Revenue/ EPS)
-100.00%
/-13.89%
Tango Therapeutics, Inc. earnings per share and revenue
On Mar 05, 2026, TNGX reported earnings of -0.28 USD per share (EPS) for Q4 25, beating the estimate of -0.32 USD, resulting in a 11.15% surprise. Revenue reached --, compared to an expected 510.41 thousand, with a -100.00% difference. The market reacted with a -9.74% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.31 USD, with revenue projected to reach -- USD, implying an increase of 10.71% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vor Biopharma Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.73
Surprise
+7.38%
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.01
Actual
$0.22
Surprise
+2278.22%
Immunic, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.93
Actual
-$1.08
Surprise
-16.03%
Humacyte, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.09
Surprise
+24.05%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
PDS Biotechnology Corporation Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.13
Surprise
+15.03%
FAQ
What were Tango Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Tango Therapeutics, Inc. reported EPS of -$0.28, beating estimates by 11.15%, and revenue of $0.00, -100% below expectations.
How did the market react to Tango Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved down -9.74%, changed from $12.63 before the earnings release to $11.40 the day after.
When is Tango Therapeutics, Inc. expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Tango Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Tango Therapeutics, Inc. is expected to report EPS of -$0.31 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement